喷昔洛韦是一种在培养的人肝癌细胞中对乙肝病毒复制有选择性抑制作用的药物。
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.
作者信息
Korba B E, Boyd M R
机构信息
Division of Molecular Virology and Immunology, Georgetown University, Rockville, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 1996 May;40(5):1282-4. doi: 10.1128/AAC.40.5.1282.
Abstract
Penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yI)guanine], an effective antiherpesvirus agent, was found to be a potent and selective antiviral agent against intracellular hepatitis B virus (HBV) replication (drug concentration at which a 10-fold decrease in HBV DNA from the average level in an untreated culture was observed [EC90], 1.6 microM) and extracellular virion release (EC90, 0.7 microM) by cultured human hepatoblastoma (2.2.15) cells. Acyclovir and three other related 9-alkoxypurines with activity against either herpesviruses or human immunodeficiency virus were uniformly inactive against HBV. The activity of penciclovir is discussed in relation to recent findings related to its mode of action against HBV.
摘要
喷昔洛韦[9-(4-羟基-3-羟甲基丁-1-基)鸟嘌呤]是一种有效的抗疱疹病毒药物，已被发现是一种针对细胞内乙型肝炎病毒(HBV)复制的强效且具有选择性的抗病毒药物(观察到将未处理培养物中的HBV DNA平均水平降低10倍时的药物浓度[EC90]为1.6微摩尔)，并且对培养的人肝母细胞瘤(2.2.15)细胞的细胞外病毒粒子释放也有抑制作用(EC90为0.7微摩尔)。阿昔洛韦以及其他三种对疱疹病毒或人类免疫缺陷病毒有活性的相关9-烷氧基嘌呤对HBV均无活性。结合最近关于喷昔洛韦抗HBV作用模式的研究结果对其活性进行了讨论。
相似文献
1
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.
Antimicrob Agents Chemother. 1996 May;40(5):1282-4. doi: 10.1128/AAC.40.5.1282.
2
Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir.
Hepatology. 1996 Nov;24(5):996-1002. doi: 10.1002/hep.510240504.
3
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Antimicrob Agents Chemother. 2003 Jun;47(6):1936-42. doi: 10.1128/AAC.47.6.1936-1942.2003.
4
Robustaflavone, a potential non-nucleoside anti-hepatitis B agent.
Antiviral Res. 1998 Aug;39(2):81-8. doi: 10.1016/s0166-3542(98)00033-3.
5
Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
J Viral Hepat. 2000 Mar;7(2):161-5. doi: 10.1046/j.1365-2893.2000.00210.x.
6
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Antimicrob Agents Chemother. 2000 Dec;44(12):3402-7. doi: 10.1128/AAC.44.12.3402-3407.2000.
7
Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Biochem Pharmacol. 1999 Jun 15;57(12):1351-9. doi: 10.1016/s0006-2952(99)00073-8.
8
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
J Virol. 2001 May;75(10):4771-9. doi: 10.1128/JVI.75.10.4771-4779.2001.
9
In vitro evaluation of combination therapies against hepatitis B virus replication.
Antiviral Res. 1996 Jan;29(1):49-51. doi: 10.1016/0166-3542(95)00915-9.
10
The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir.
Antiviral Res. 1999 Jan;40(3):167-78. doi: 10.1016/s0166-3542(98)00059-x.
引用本文的文献
1
Antiviral Chemotherapy in Avian Medicine-A Review.
Viruses. 2024 Apr 12;16(4):593. doi: 10.3390/v16040593.
2
Biophysical and In Silico Studies of the Interaction between the Anti-Viral Agents Acyclovir and Penciclovir, and Human Serum Albumin.
Molecules. 2017 Nov 5;22(11):1906. doi: 10.3390/molecules22111906.
3
5-Fluoro-1-[(4S,5R)-5-(2-hydroxy-ethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]pyrimidine-2,4(1H,3H)-dione.
Acta Crystallogr Sect E Struct Rep Online. 2010 May 12;66(Pt 6):o1317. doi: 10.1107/S1600536810016065.
4
An experiment on standardized cell culture assay in assessing the activities of Composite Artemisia Capillaris Tablets against hepatitis B virus replication in vitro.
Chin J Integr Med. 2005 Mar;11(1):54-6. doi: 10.1007/BF02835751.
5
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Antimicrob Agents Chemother. 2003 Jun;47(6):1936-42. doi: 10.1128/AAC.47.6.1936-1942.2003.
6
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Antimicrob Agents Chemother. 2001 Jun;45(6):1705-13. doi: 10.1128/AAC.45.6.1705-1713.2001.
7
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Antimicrob Agents Chemother. 2000 Dec;44(12):3402-7. doi: 10.1128/AAC.44.12.3402-3407.2000.
8
Combination chemotherapy for hepatitis B virus: the path forward?
Drugs. 2000 Sep;60(3):517-31. doi: 10.2165/00003495-200060030-00001.
9
Treatment of chronic hepatitis B: new antiviral therapies.
Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):20-6. doi: 10.1007/s11894-999-0082-7.
10
Lamivudine. A review of its therapeutic potential in chronic hepatitis B.
Drugs. 1999 Jul;58(1):101-41. doi: 10.2165/00003495-199958010-00015.
本文引用的文献
1
Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.
J Antimicrob Chemother. 1994 Jan;33(1):119-27. doi: 10.1093/jac/33.1.119.
2
In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.
Antimicrob Agents Chemother. 1994 Apr;38(4):719-23. doi: 10.1128/AAC.38.4.719.
3
Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
J Med Virol. 1994 Mar;42(3):306-10. doi: 10.1002/jmv.1890420319.
4
Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action.
Biochemistry. 1995 Feb 28;34(8):2504-10. doi: 10.1021/bi00008a014.
5
Safety of famciclovir in patients with herpes zoster and genital herpes.
Antimicrob Agents Chemother. 1994 Oct;38(10):2454-7. doi: 10.1128/AAC.38.10.2454.
6
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro.
Antimicrob Agents Chemother. 1994 Sep;38(9):2172-4. doi: 10.1128/AAC.38.9.2172.
7
Acyclovir, oral, intravenous and combined with interferon for chronic HBeAg-positive hepatitis.
J Hepatol. 1986;3 Suppl 2:S137-41. doi: 10.1016/s0168-8278(86)80112-x.
8
Controlled clinical trial of acyclovir in chronic hepatitis B virus infection.
J Med Virol. 1987 Jan;21(1):81-7. doi: 10.1002/jmv.1890210111.
9
Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions.
J Virol. 1988 Aug;62(8):2836-44. doi: 10.1128/JVI.62.8.2836-2844.1988.
10
In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus.
Antimicrob Agents Chemother. 1989 Mar;33(3):336-9. doi: 10.1128/AAC.33.3.336.
Zotero 插件